Patents by Inventor Malcolm K. Brenner

Malcolm K. Brenner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210077530
    Abstract: Embodiments of the disclosure concern engineered auto/allo-immune defense receptor (ADR)-expressing T cells that selectively target activated T cells, including pathogenic T cells, to incapacitate them. The chimeric receptors comprise moieties for targeting 4-1BB, 0X40, and CD40L, for example, whose expression is indicative of activated T cells. In particular embodiments, there are methods of preventing or treating conditions associated with activated T cells using adoptive T-cell transfer of cells encoding the ADRs.
    Type: Application
    Filed: April 25, 2019
    Publication date: March 18, 2021
    Inventors: Maksim Mamonkin, Malcolm K. Brenner, Feiyan Mo
  • Publication number: 20200405811
    Abstract: Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 31, 2020
    Inventors: Maksim Mamonkin, Malcolm K. Brenner
  • Publication number: 20200323932
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Application
    Filed: April 20, 2018
    Publication date: October 15, 2020
    Applicant: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Patent number: 10786549
    Abstract: Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: September 29, 2020
    Assignee: Baylor College of Medicine
    Inventors: Maksim Mamonkin, Malcolm K. Brenner
  • Patent number: 10716818
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: July 21, 2020
    Assignee: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Publication number: 20200030421
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 30, 2020
    Inventors: Malcolm K. Brenner, Jack James
  • Publication number: 20200016207
    Abstract: Embodiments of the present disclosure concern improvements to cell therapy for cancer. In certain embodiments, an immune cell lacks expression of hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), and supplementation of this effect allows an improvement for cancer cell therapy, including of hematological malignancies. In specific embodiments, immune cells comprise recombinant c-MPL expression or parts thereof and the cells have enhanced co-stimulation and cytokine signals and improved activation, persistence, and anti-tumor function compared to cells that lack recombinant c-MPL expression.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 16, 2020
    Inventors: Caroline Eva Arber Barth, Malcolm K. Brenner
  • Publication number: 20190374589
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 12, 2019
    Applicant: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Publication number: 20190263928
    Abstract: Embodiments of the disclosure include methods and compositions that allow for development of efficient chimeric antigen receptors (CARs) by selecting appropriate spacer content and/or length by balancing the effects of tonic signaling with the efficacy of antigen recognition for the spacer. In specific embodiments, the CH3 domain from IgG2 is utilized as a spacer. In specific embodiments, T cell metabolic activity is utilized as a measure of tonic signaling to facilitate determination of suitable CAR constructs. In other embodiments, cells bearing chimeric Fc receptor target molecules are utilized to target Fc gamma receptor (FcR)-bearing for the purpose of their destruction.
    Type: Application
    Filed: September 29, 2017
    Publication date: August 29, 2019
    Inventors: Norihiro Watanabe, Malcolm K. Brenner, Juan Fernando Valdes Vera
  • Publication number: 20180344828
    Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.
    Type: Application
    Filed: October 31, 2016
    Publication date: December 6, 2018
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine
    Inventors: Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner
  • Publication number: 20180271961
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Application
    Filed: March 14, 2018
    Publication date: September 27, 2018
    Inventor: Malcolm K. BRENNER
  • Publication number: 20180243385
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 30, 2018
    Inventor: Malcolm K. BRENNER
  • Publication number: 20180104308
    Abstract: Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.
    Type: Application
    Filed: April 22, 2016
    Publication date: April 19, 2018
    Inventors: Maksim Mamonkin, Malcolm K. Brenner
  • Patent number: 9393292
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: July 19, 2016
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventor: Malcolm K. Brenner
  • Publication number: 20150366954
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 24, 2015
    Inventor: Malcolm K. Brenner
  • Patent number: 9089520
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: July 28, 2015
    Assignee: Baylor College of Medicine
    Inventor: Malcolm K. Brenner
  • Publication number: 20130071414
    Abstract: The present invention generally concerns particular methods and compositions for cancer therapy. In particular embodiments, there methods and compositions related to cells that harbor expression vectors encoding a cytokine and an inducible suicide gene and, optionally, the same or different vector(s) encoding a chimeric antigen receptor and/or a detectable gene product.
    Type: Application
    Filed: April 27, 2012
    Publication date: March 21, 2013
    Inventors: Gianpietro Dotti, David M. Spencer, Cliona M. Rooney, Malcolm K. Brenner
  • Patent number: 8178504
    Abstract: The present invention pertains to compositions and methods useful for treating anemia and other effects that are commonly associated in cancer bearing animals. The invention is accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: May 15, 2012
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Robert J. Schwartz, Glen King, Kevin Hahn, Malcolm K. Brenner
  • Publication number: 20110286980
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Inventor: Malcolm K. Brenner
  • Publication number: 20090170748
    Abstract: The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and methods are useful for treating anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the animal tissue specific constitutive expression is achieved.
    Type: Application
    Filed: March 21, 2007
    Publication date: July 2, 2009
    Applicants: Advisys, Inc., Baylor College of Medicine
    Inventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Robert J. Schwartz, Glen King, Kevin Hahn, Malcolm K. Brenner